Adrian W. Quartel, Chief Medical Officer at Zevra Therapeutics (NASDAQ: ZVRA), reported a sale of 4,533 shares of common stock on January 30, 2026. The transaction amounted to approximately $40,035, executed at a weighted average price of $8.8321 per share. Individual sale prices recorded in the filing ranged from $8.62 to $9.04.
The publicly filed Form 4 for the transactions details additional equity movements concurrent with the sale. Quartel was granted 37,500 restricted stock units and 75,000 stock options as part of the reported activity, and he exercised options to acquire 11,333 shares of common stock. After the sale and these exercises and grants, Quartel's direct holdings total 9,723 shares of Zevra common stock.
Market context included in the filing and company metrics indicates the stock is trading at $9.36, roughly 4% higher than the weighted average price at which Quartel sold shares. Over the past year the equity has returned 22.35 percent. Data from InvestingPro cited in company commentary suggests Zevra may be slightly undervalued relative to a Fair Value assessment used by that service.
Corporate fundamentals highlighted alongside the filing show a market capitalization of $526.94 million and a reported revenue increase of 244.6 percent over the last twelve months. The company's balance sheet is described as holding more cash than debt, and InvestingPro analysis is noted to rate Zevra's overall financial health positively. Analyst price targets referenced fall in a range between $18 and $26 per share, which sit materially above the current trading level.
Operational and commercial developments referenced in the same company update include third-quarter 2025 financial results. Zevra reported earnings per share of -$0.01 for that quarter, beating the consensus estimate of -$0.03, while revenue for the period was $26.1 million, marginally below the projected $26.64 million. Separately, Zevra announced an exclusive expanded access distribution agreement with Uniphar to broaden the reach of its expanded access program for Miplyffa (arimoclomol) to additional territories for patients with Niemann-Pick Disease Type C.
Following those developments, H.C. Wainwright reiterated a Buy rating on Zevra Therapeutics with a price target of $26.00. The mix of insider transactions, equity awards, recent financial performance and strategic distribution steps are captured in filings and analyst commentary disclosed alongside the company updates.
Note: The details above reflect the transactions and company disclosures as reported in the filed documents and company communications.